Next Article in Journal
Simultaneous Determination of Procainamide and N-acetylprocainamide in Rat Plasma by Ultra-High-Pressure Liquid Chromatography Coupled with a Diode Array Detector and Its Application to a Pharmacokinetic Study in Rats
Previous Article in Journal / Special Issue
Nose-to-Brain Delivery of Antiviral Drugs: A Way to Overcome Their Active Efflux?
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(2), 40; https://doi.org/10.3390/pharmaceutics10020040

In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases

Department of Chemistry, University of Fort Hare, Alice Campus, Eastern Cape, Alice 5700, South Africa
Received: 13 January 2018 / Revised: 17 February 2018 / Accepted: 22 February 2018 / Published: 30 March 2018
(This article belongs to the Special Issue Nose to Brain Delivery)
View Full-Text   |   Download PDF [1020 KB, uploaded 30 March 2018]   |  

Abstract

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges. View Full-Text
Keywords: nose-to-brain delivery; neurological diseases; drug delivery systems; in situ-based gels; brain tumor; Alzheimer’s disease nose-to-brain delivery; neurological diseases; drug delivery systems; in situ-based gels; brain tumor; Alzheimer’s disease
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Aderibigbe, B.A. In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases. Pharmaceutics 2018, 10, 40.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top